Cargando…
Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disorder with a variable disease course. The recent advancement of antifibrotic therapy has increased the need for reliable and specific biomarkers. This study aimed to assess alveolar epithelial biomarkers as predictors for the...
Autores principales: | Ikeda, Kimiyuki, Chiba, Hirofumi, Nishikiori, Hirotaka, Azuma, Arata, Kondoh, Yasuhiro, Ogura, Takashi, Taguchi, Yoshio, Ebina, Masahito, Sakaguchi, Hiroki, Miyazawa, Shogo, Suga, Moritaka, Sugiyama, Yukihiko, Nukiwa, Toshihiro, Kudoh, Shoji, Takahashi, Hiroki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7706186/ https://www.ncbi.nlm.nih.gov/pubmed/33256760 http://dx.doi.org/10.1186/s12931-020-01582-y |
Ejemplares similares
-
The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial
por: Taniguchi, Hiroyuki, et al.
Publicado: (2011) -
Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment
por: Azuma, Arata, et al.
Publicado: (2011) -
Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
por: Yoshikawa, Takumi, et al.
Publicado: (2020) -
Transcription repressor Bach2 is required for pulmonary surfactant homeostasis and alveolar macrophage function
por: Nakamura, Atsushi, et al.
Publicado: (2013) -
Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
por: Yoshikawa, Takumi, et al.
Publicado: (2020)